Translational Andrology and Urology

Editorial

• Refining treatment for the men who need it: lessons from the PIVOT trial
• Michael R. Abern, Matvey Tsivian, Thomas J. Polascik
• • Abstract
  • PDF

• Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?
• Ilse Van Brussel, Amaryllis H. Van Craenenbroeck, Dorien M. Schrijvers, Nathalie Cools
• • Abstract
  • PDF

• Immunotherapy in renal cell cancer: the more the merrier?
• Jorge Camarero, Sol Ruiz
• • Abstract
  • PDF

• Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
• Matthias M. Heck, Jürgen E. Gschwend, Margitta Retz
• • Abstract
  • PDF

Research Highlight

• Tivozanib: A novel VGFR inhibitor for kidney cancer
• Helen Boyle
• • Abstract
  • PDF

• Enzalutamide: the emperor of all anti-androgens
• Emmanuel S. Antonarakis
• • Abstract
  • PDF

• Identification of biomarkers in pazopanib treated patients with renal cell carcinoma
• Amy M Pick, Zara Risoldi Cochrane
• • Abstract
  • PDF

Opinion

• Regenerative technology for future therapy of erectile dysfunction
• Ji-Kan Ryu, Jun-Kyu Suh
• • Abstract
  • PDF